Daniel K. Hall‐Flavin

Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting

Daniel K. Hall‐Flavin, Joel G Winner, Josiah D. Allen et al. · Pharmacogenetics and Genomics · 2013 · 202 citations

Using a pharmacogenomic algorithm to guide the treatment of depression

Daniel K. Hall‐Flavin, Joel G Winner, Josiah D. Allen et al. · Translational Psychiatry · 2012 · 178 citations · Full text

The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response

Joanna M. Biernacka, Katrin Sangkuhl, Gregory D. Jenkins et al. · Translational Psychiatry · 2015 · 139 citations · Full text

TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics

M Gupta, Drew Neavin, Duan Liu et al. · Molecular Psychiatry · 2016 · 116 citations · Full text

Genetics, Genetic Epidemiology, Psychopharmacology +20

Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes

C. Anthony Altar, Joseph Carhart, Josiah D. Allen et al. · The Pharmacogenomics Journal · 2015 · 111 citations

Psychiatry, Clinical Validity, Psychotropic Medication +12